Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles: Therapeutics, Targets, and Development

C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer

Elizabeth E. Evans, Alicia D. Henn, Alan Jonason, Mark J. Paris, Linda M. Schiffhauer, Melinda A. Borrello, Ernest S. Smith, Deepak M. Sahasrabudhe and Maurice Zauderer
Elizabeth E. Evans
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alicia D. Henn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Jonason
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark J. Paris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda M. Schiffhauer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melinda A. Borrello
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ernest S. Smith
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deepak M. Sahasrabudhe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maurice Zauderer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-06-0389 Published November 2006
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Northern blots showing mRNA expression in mammary carcinoma cell lines, compared with H16N2, an immortalized cell line derived from normal breast epithelial tissue. The 32P-labeled probe consisted of the open reading frame of C35 transcript (top). C35 expression in each cell line is normalized to housekeeping (HK) gene β-actin (bottom left and middle) and/or GAPDH (bottom right).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    C35 protein sequence is conserved among species. National Center for Biotechnology Information accession numbers are as follows: Homo sapiens, AY508814; Rhesus monkey Macaca mulatta, XP_001091012; Mus musculus, NP_079835; Rattus norvegicus, XP_001081367; Bos taurus, XP_582041; Canis familiaris, XP_537653; Xenopus tropicalis, NP_001015996. A predicted prenylation site (CVIL) is bolded and italicized. The immunoreceptor tyrosine-based activation consensus sequence is in bold.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Chromosomal location of C35. The C35 gene is located on chromosome 17q12, 7402 nucleotides from the start of GRB7 and 505 nucleotides from the end of ERBB2. Direction of transcription is denoted by arrows, and positions of each gene on the chromosome are identified based on Human Genome build 36.1. The full-length C35 transcript is 730 nucleotides in length, consisting of four exons (black boxes).

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    A, anti-C35 antibody specifically binds endogenous C35 protein in Western blot analysis. C35 protein was detected using rabbit polyclonal antiserum B78-2 in lysates of C35hi tumor 21MT-1 but not in C35lo “normal” breast cell line H16N2. Binding can be competed by preincubation of the antiserum with purified C35 protein, showing specificity of the antibody in the assay. Corresponding fast green stains of the blots show equal sample loading and transfer. Molecular weight markers (kDa) are indicated with arrows. B, immunohistochemistry of cell lines derived from metastatic breast carcinoma and normal breast epithelium. Sections of formalin-fixed, paraffin-embedded cell pellets were stained with polyclonal rabbit anti-C35 or isotype control rabbit IgG antibodies. Tumor stains intensely with a punctate pattern. Magnification, ×100.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    C35 transcript regulation. Cell lines were analyzed for abundance of C35 gene or transcript by real-time PCR to compare genomic amplification with expression of mRNA. All genomic amplification data are relative to H16N2, which is set to reflect one copy. The C35/ERBB2 locus is amplified in 21MT-1, corresponding with overexpression of both transcripts in this line. In contrast, C35 transcript is overexpressed in Colau without amplification of the gene locus. Furthermore, luciferase activity driven by C35 promoter region mimics cDNA levels and contrasts with genomic copy number in C35+ cell lines, such as Colau and Mel1700.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Immunohistochemistry of intraductal carcinoma of breast. A, sections of formalin-fixed, paraffin-embedded tissue were stained with polyclonal rabbit anti-C35, anti-c-erb-B2, or isotype control antibodies. Top, example of a C35+/ERBB2+ tumor (scores of 4+ and 3+, respectively); bottom, example of a C35+/ERBB2− tumor (scores 2+ and 0, respectively; faint cytoplasmic stain is negative according to HercepTest guidelines). ERBB2+ tumor has intense plasma membrane staining, whereas C35+ tumors show intense, homogeneous, cytoplasmic staining. Magnification, ×40. B, comparison of immunohistochemistry scores for HER-2/neu and C35 in number of IDC cases. Dotted lines indicate delineation between positive and negative scores.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Normal human tissues stained with rabbit anti-C35 polyclonal antibodies (top) and control rabbit IgG (bottom). Magnification, 40×. A, breast tissue from a non-cancer patient. B, breast tissue from cancer patient containing tumor (4+, red arrows) and adjacent morphologically “normal” epithelium (2+, black arrows). Inset, magnification, ×100. C, testes, Leydig cells are C35+ (blue arrows). D, heart. E, liver (polymer detection). F, lung. G, kidney. H, ovary. I, uterus. J, prostate. K, salivary gland.

  • Figure 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 8.

    C35 positivity correlates with age in ILC. C35 is expressed at a higher frequency in young patients with ILC. Expression in IDC does not correlate with patient age.

  • Figure 9.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 9.

    C35 Expression in breast metastases. Examples of distant metastases stained with polyclonal rabbit anti-C35 or control IgG. Magnification, ×40.

Tables

  • Figures
  • Table 1.

    C35 expression in FFPE breast tissue sections was determined by immunohistochemistry

    nHER-2/neu+ (%)C35+ (%)Mean C35 reactivityP (one-sample paired t)
    Intraductal carcinoma
        Qualtek study572153
        AccuMax Array302040
        Asterand Array
    71
    20
    38


        Total IDC15820*441.46†<0.0001
        Low grade (1)220320.73
        High grade (2 and 3)3534662.03†<0.0001
        Stage I2811180.93
        Stage II3824471.63†<0.0001
        Stage III2619381.46†0.0035
        Stage IV425501.75
    Lobular carcinoma
        Qualtek Study14050
        AccuMax Array4025
        Asterand Array
    22
    5
    32


        Total ILC405‡381.16†0.0083
    Papillary carcinoma: AccuMax813*501.13
    Medullary carcinoma: Asterand600
    Mucinous carcinoma: Asterand2050
    Normal breast tissue
        Adjacent normal4013
        Normal breast1735
        Total normal breast57190.61
    • ↵* All HER-2/neu+ samples are also C35+.

    • ↵† Significant difference compared with expression in normal breast by paired t test (P < 0.05).

    • ↵‡ The two HER-2/neu+ samples are C35−.

PreviousNext
Back to top
Molecular Cancer Therapeutics: 5 (11)
November 2006
Volume 5, Issue 11
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer
Elizabeth E. Evans, Alicia D. Henn, Alan Jonason, Mark J. Paris, Linda M. Schiffhauer, Melinda A. Borrello, Ernest S. Smith, Deepak M. Sahasrabudhe and Maurice Zauderer
Mol Cancer Ther November 1 2006 (5) (11) 2919-2930; DOI: 10.1158/1535-7163.MCT-06-0389

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer
Elizabeth E. Evans, Alicia D. Henn, Alan Jonason, Mark J. Paris, Linda M. Schiffhauer, Melinda A. Borrello, Ernest S. Smith, Deepak M. Sahasrabudhe and Maurice Zauderer
Mol Cancer Ther November 1 2006 (5) (11) 2919-2930; DOI: 10.1158/1535-7163.MCT-06-0389
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
  • Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors
  • WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells
Show more Research Articles: Therapeutics, Targets, and Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement